Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.
In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.
Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.
The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.
Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.
If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCycler™-Fusion system, revolutionizing spatial biology with its ability to map a million cells in just 10 minutes. This integrated platform combines high-speed imaging and ultrahigh multiplex cycling, allowing researchers to conduct large-scale biomarker discovery and validation efficiently. It can process over 300 samples weekly and incorporates RNA detection for comprehensive tissue analysis. The system enhances existing products, promising unbiased, rapid mapping of cellular interactions related to diseases.
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced preliminary unaudited revenues for Q4 and full year 2021, with Q4 revenue expected between $16.0 million and $16.2 million, up from $12.9 million in Q4 2020. Full year revenue forecasts are between $54.8 million and $55.0 million, compared to $42.4 million in 2020. CEO Brian McKelligon highlighted significant progress, including a 30% revenue growth, an IPO, and near doubling of the company’s workforce. Despite these positive indicators, actual results remain subject to quarter-end adjustments.
Akoya Biosciences partners with Bio-Techne to develop the first single-cell, spatial multiomics workflow, enhancing the analysis of tissue samples. The PhenoCycler™-Fusion system, launching early January 2022, will automate protein and RNA imaging through RNAScope® technology. This collaboration aims to accelerate research in human health and complex diseases, offering new biomarker diagnostic signatures and improving treatment outcomes. Over 4,500 peer-reviewed publications back RNAScope assays, establishing them as a standard for spatial RNA imaging.
Bio-Techne (NASDAQ: TECH) and Akoya Biosciences (NASDAQ: AKYA) announced a partnership to develop a groundbreaking automated spatial multiomics workflow for tissue sample analysis. The collaboration aims to enhance RNA and protein analysis at single-cell resolution, facilitating better biomarker discovery and patient stratification in diseases like cancer. The partnership leverages Akoya's PhenoCycler-Fusion System and Bio-Techne's RNAScope HiPlex v2 assay, promising to accelerate research and improve treatment outcomes for complex diseases.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2022, at 9:00 a.m. ET. Brian McKelligon, CEO, will present the company's insights and developments. Investors can access both live and archived webcasts of this event through the Akoya website. As a leader in spatial biology, Akoya aims to enhance understanding of human health and disease through its innovative single-cell imaging solutions, including the CODEX® and Phenoptics™ platforms.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced a suite of innovations aimed at enhancing spatial biology research. Key highlights include the launch of the PhenoCycler-Fusion System, which enables mapping a million cells in under 10 minutes. The system combines ultrahigh multiplex cycling technology and high-speed imaging, allowing for faster and more detailed spatial discovery. Akoya will also introduce novel RNA and protein chemistries, facilitating comprehensive multiomic assessment. The commercial launch of the PhenoCycler-Fusion is set for January 2022, following limited distribution in December 2021.
Akoya Biosciences (Nasdaq: AKYA) and PathAI have partnered to enhance the discovery of predictive biomarkers for immunotherapies. This collaboration utilizes Akoya's Phenoptics™ spatial phenotyping platform and PathAI's AI algorithms to aid biopharmaceutical companies in identifying patients likely to respond to clinical trial treatments. The partnership aligns with Akoya's recent CLIA certification and aims to revolutionize cancer treatment through improved efficacy rates in immuno-oncology. Key insights into tumor microenvironments will accelerate drug development and clinical trials.
Akoya Biosciences (Nasdaq: AKYA) has achieved CLIA certification for its Advanced Biopharma Solutions laboratory in Marlborough, Massachusetts. This certification allows Akoya to support later-stage clinical trials and enhances its ability to develop and validate assays to meet high-quality standards. The certification positions Akoya as a valuable partner to biopharmaceutical companies, particularly in cancer immunotherapy. This advance follows prior milestones, including a publication demonstrating Akoya's spatial biology technology's effectiveness in clinical settings.
Akoya Biosciences, known as The Spatial Biology Company, will hold its inaugural Spatial Day on December 15, 2021, at 12 p.m. ET. This event will showcase recent advancements in spatial biology, emphasizing its potential in discovery and clinical research. Key speakers include Akoya's CEO Brian McKelligon and leading experts from renowned institutions. Topics will cover disease biology and the future role of spatial biomarkers in transforming healthcare solutions. Interested participants can register at www.akoyabio.com/spatialday.
Akoya Biosciences (AKYA) reported record Q3 2021 revenue of $13.5 million, a 35% increase year-over-year. Product revenue reached $10.9 million, up 38%, while services generated $2.6 million. Gross profit surged to $8.5 million with a margin of 62.7%. The company installed 33 instruments in Q3, contributing to a total of 651 instruments worldwide. With $120.2 million in cash, Akoya maintains strong growth momentum and raised its full-year revenue guidance to at least $53.8 million.
FAQ
What is the current stock price of Akoya BioSciences (AKYA)?
What is the market cap of Akoya BioSciences (AKYA)?
What does Akoya BioSciences, Inc. do?
What are Akoya's core products?
How did Akoya perform financially in 2023?
Who are some of Akoya's key partners?
What recent achievements has Akoya announced?
How many publications have cited Akoya's technology?
What is Akoya's financial outlook for 2024?
What is the significance of the new Manufacturing Center of Excellence?
Who should consider working at Akoya BioSciences?
How can one contact Akoya BioSciences for more information?
